Press Release: Sarclisa approved in the US as the first anti ... - Sanofi
WEB3 days ago · Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. 1 Kazandjian. Multiple myeloma epidemiology and survival: A unique malignancy.
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma ...
WEB12 hours ago · On Saturday, the FDA approved Sanofi’s SA (NASDAQ:SNY) Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option for adult ...
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
WEB9 hours ago · REGN. Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in ...
Sanofi wins US approval for multiple myeloma drug in newly …
WEB3 days ago · Sept 20 - The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's (SASY.PA) Sarclisa infusion as a treatment for certain types of ...
Press Room - Sanofi US News
WEB4 days ago · Advancing SARCLISA in multiple myeloma. Sanofi continues to advance SARCLISA as part of a patient-centric clinical development program, which includes several phase 2 and phase 3 studies across the MM treatment …
Sanofi moves on J&J in first-line myeloma with FDA nod
WEB3 days ago · ASCO: With first-in-class win, Sanofi's Sarclisa looks to step out of J&J's multiple myeloma shadow. Challenging Darzalex won’t be easy. Worldwide sales of the J&J med jumped 22% and reached $9. ...
Press Room - Sanofi US News
WEBAug 8, 2024 · Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant.
Press Room - Sanofi US News
WEBMay 27, 2024 · About multiple myeloma. Multiple myeloma (MM) is the second most common hematologic malignancy, 2 with more than 180,000 new diagnoses of MM worldwide yearly. 3 Despite available treatments, MM remains an incurable malignancy with an estimated 52% five-year survival rate for newly diagnosed patients. 4 Since MM does not have a cure, most ...
Press Release: Sarclisa accepted for FDA priority review for ... - Sanofi
WEBMay 27, 2005 · Sarclisa is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on multiple myeloma (MM) cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activities.
FDA Approves Sarclisa with VRd | Int'l Myeloma Foundation
WEB4 days ago · According to a September 20, 2024, press release, the U.S. Food and Drug Administration (FDA) has "approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT)." This approval was based on results of the phase III IMROZ clinical trial ...
- Some results have been removed
Skip to content